Study explores GABA-enriched almond yogurt for stress support

A newly published study in Frontiers in Veterinary Science reports the production of a GABA-enriched almond yogurt using Enterococcus faecalis RIT BMS15-3, a psychobiotic candidate isolated from human breast milk. The researchers say the product was designed as a functional food aimed at stress modulation through the microbiota-gut-brain axis, and they report that optimized fermentation produced 29 mM GABA while preserving probiotic viability and product stability during refrigerated storage. The article was published September 21, 2026. (frontiersin.org)

The work lands amid broader interest in diet-based approaches to behavioral and stress support, both in human health and in veterinary medicine. Over the past several years, psychobiotics, probiotics thought to influence mental health through gut-brain signaling, have become a more visible topic in companion animal nutrition. Recent veterinary commentary has highlighted evidence that some probiotic interventions may affect stress-related pathways, including cortisol and serotonin, although the mechanisms and clinical relevance are still being worked out. (dvm360.com)

In this study, the novelty is fairly narrow but still notable. The authors are careful to say this is not the first GABA-enriched plant-based fermented product, or even the first almond-based product in the category. Instead, they position the advance as the first use of this specific human breast milk-derived E. faecalis strain in an almond yogurt matrix, with fermentation variables optimized specifically for microbial GABA biosynthesis rather than mainly for texture or general product quality. They report favorable water-holding capacity, viscosity, an overall sensory score of 7.52, and retained GABA and viable probiotic counts over 21 days of storage. (frontiersin.org)

The strain itself also has an important backstory. In a separate 2026 Frontiers in Microbiology paper, the same isolate was identified as Enterococcus faecalis RIT BMS15-3 after screening breast milk-derived candidates for GABA production. That earlier paper reported gastrointestinal stress tolerance and other probiotic attributes, but it also noted that whole-genome sequencing had not been done, and that genomic analysis would be needed for more precise safety characterization. (frontiersin.org)

That safety point matters. Enterococci occupy an uneasy place in probiotic science: some strains have been used in probiotic products, but the genus also raises longstanding concerns around virulence traits and antimicrobial resistance, which is why safety assessment has to be strain-specific and rigorous. Reviews in companion animal medicine have noted that Enterococcus use is restricted in some jurisdictions because of infection and AMR gene-transfer concerns, and broader probiotic guidance for veterinary practice continues to stress quality control and careful product selection. (pmc.ncbi.nlm.nih.gov)

Industry and expert commentary around psychobiotics suggests why this paper may draw attention despite its early-stage nature. In a recent dvm360 interview, Callie Harris, DVM, described psychobiotics as an emerging area in which gut microbiota may influence mood through bidirectional gut-brain signaling, pointing to evidence of reduced cortisol and increased serotonin in some pet-focused probiotic studies. That doesn’t validate this almond yogurt specifically, but it does show that the veterinary nutrition conversation is moving toward microbiome-mediated behavioral support, especially for stress and anxiety management. (dvm360.com)

Why it matters: For veterinary professionals, this is best read as a platform study, not a practice-changing nutrition tool. It expands the functional-food conversation by combining plant-based fermentation, microbial GABA production, and psychobiotic framing in a veterinary journal. Still, there are several gaps between bench formulation and clinical use: no dog or cat data, no demonstrated behavioral effect, no clinical stress endpoints, and unresolved questions about regulatory pathway and strain-level safety characterization. For clinicians and industry teams, the takeaway is less about recommending almond yogurt and more about watching how microbiome-targeted nutrition is being engineered toward behavior and stress outcomes. (frontiersin.org)

What to watch: The next phase to watch is whether the authors, or commercial partners, move into in vivo studies with companion animals, add whole-genome safety data for the strain, and test whether GABA-enriched fermented products can produce measurable changes in stress biomarkers, GI function, or behavior under real-world feeding conditions. (frontiersin.org)